Revenue grew 16% year-over-year to $32.6M, with gross margin expanding to 65% and a return to operating profitability. Commercial and OEM channels both saw double-digit growth, and FY 2026 guidance was raised on improved operational efficiencies and product demand.Original document: Anika Therapeut…
Revenue grew 16% year-over-year to $32.6M, with gross margin expanding to 65% and a return to operating profitability. Commercial and OEM channels both saw double-digit growth, and FY 2026 guidance was raised on improved operational efficiencies and product demand.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.